复宏汉霖的私有化为何被终止?

医药财经
22 Jan

2025年1月22日,复星医药发布公告称:公司关于吸收合并及私有化复宏汉霖的特别决议案未达成,吸收合并将不予实施,复宏汉霖将保留H股上市地位。这是继海尔生物终止并购上海莱士之后,又一起披露重组事项而有终止的案例。那么,复星医药及复宏汉霖为何要“出尔反尔”?经医药财经AI分析推测,复宏汉霖的私有化终止主要是由于以下几个关键因素:投票结果未达标准:在H股类别股东大会上,复星医药提出的私有化提案未能获得...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10